Share this hemophilia module with anyone interested in how to care for a patient with hemophilia from birth to transition! My former #ASHMEI project and #ASPHO clinician educator award project. https://t.co/9TbthLcmMJ
Our dear friends that support pediatric cancer @CourageofCarly, @RoswellPark@PUNTpedcancer, & bereavement programs have had a serious 🔥This cause is dear to my ❤️. Please donate and share!! Fundraiser: Rebuilding Stillwater Farm (the Braymiller family) https://t.co/ObbFFvSiPF
My beloved second home, where my goats live. So thankful ALL animals and humans are safe! So sad for my friends that had to go through such a traumatic experience. ❤️But it will be rebuilt and better than ever!
Had an incredible time at #ASHMEI at @ASH_hematology headquarters in Washington, DC this week. Lots of learning was accomplished, projects were developed, and lifelong friends and mentors were made!
Success of Low-dose emi in resource limited setting 🇮🇳 brings up options for dose reduction in certain risk populations. Reduced💰than current SOC (low dose FVIII, standard dose emi). #ISTH2023
Dr Betensky shares sub analysis of KIDS-DOTT: 22% w APL at diagnosis, 2.5% w persistent + at 12w. One w triple +APS. Majority single + (PTT-LA and drvvt). Higher rates of infection as provoking event. #ISTH2023
Children on apixiban in PREVAPIX-ALL with ⬇️ d-dimer. F1.2, APC-PCI. Comparable fibrin generation to SOC may balance the AC effect resulting in similar rates of bleeding. #ISTH2023
Biomarkers in children undergoing Induction for ALL on PREVAPIX study (SOC). Consistent hypercoagulable state w elev FVIII, alterations in thrombin & fibrin generation, and ⬇️ fibrinogen. #ISTH2023
CYP-C with ~2% VTE in induction for pediatric ALL. No assoc w induction failure, or tx intensification, but continues to be assoc w mortality.#ISTH2023